Showing 2901-2910 of 4107 results for "".
- Practical Dermatology Magazine Mourns the Passing of Two Preeminent Dermatologistshttps://practicaldermatology.com/news/practical-dermatology-mourns-the-passing-of-two-preeminent-dermatologists/2460741/By Wendy Lewis It is with great sadness that Practical Dermatology® magazine pays our respects to two very talented and respected dermatologists, Melanie Grossman, MD and Marta Rendon, MD.
- Now Cleared for Neck Treatments: SkinPen Precisionhttps://practicaldermatology.com/news/skinpen-cleared-for-neck-treatments/2460740/SkinPen® Precision from Crown Aesthetics is now cleared for the treatment of wrinkles on the neck. The FDA clearance is based on results of a recent single-center clinical study, which demonstrated clinical improvement of dermal lines on the neck and high patient satisfaction at one and
- Dermatological Advocates Present Dr. Adam Friedman with Advocacy Leadership Awardhttps://practicaldermatology.com/news/dermatological-advocates-present-dr-adam-friedman-with-advocacy-leadership-award/2460738/The Derma Care Access Network (DCAN), a national non-profit coalition advocating for patient access to optimal dermatological care, is recognizing Adam Friedman, MD with its inaugural Advocacy Leadership Award for his work as a passionate advocate and
- Study Documents Arm, Skin Rashes After COVID-19 Vaccinationshttps://practicaldermatology.com/news/study-documents-covid-vaccine-arm-skin-rashes-after-covid-19-vaccinations/2460737/As COVID-19 vaccination ramps up globally, new research in the Journal of the American Academy of Dermatology demonstrates the wide variety of skin rashes, including full-body rashes, observed after COVID
- FDA Grants 510(k) Clearance to Chemence Medical’s Exofin Fusion Redesignhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-chemence-medicals-exofin-fusion-redesign/2460736/The U.S. Federal Drug Administration gave its nod to Chemence Medical’s redesigned exofin fusion skin closure system. Exofin fusion combines a self-adhering flexible mesh strip and a fast-curing 2-octyl cyanoacrylate topical adhesive to close and seal incisions while forming an im
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon
- Verrica CMO Dr. Gary Goldenberg Elected to Membership in the American Dermatological Associationhttps://practicaldermatology.com/news/verrica-cmo-dr-gary-goldenberg-elected-to-membership-in-the-american-dermatological-association/2460728/Gary Goldenberg, MD has been elected as an active member into the American Dermatological Association (ADA). Dr. Goldenberg is Verrica’s Chief Medical Officer. “We congratulate Gary on his well-deserved election into the ADA, one of the highest honors in d
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- Kenneth J. Tomecki, MD, FAAD is New President of the AADhttps://practicaldermatology.com/news/kenneth-j-tomecki-md-faad-is-new-president-of-the-aad/2460723/Kenneth J. Tomecki, MD, FAAD is now president of the American Academy of Dermatology (AAD). During his one-year term, Dr. Tomecki will lead the world’s largest dermatologic society, representing more than 20,000 physicians specializing
- Two-Year Data Confirm Benefits, Safety of Tremfya in PsA and PsOhttps://practicaldermatology.com/news/two-year-data-confirm-benefits-safety-of-tremfya-is-psa-and-pso/2460722/Long-term data from the Phase 3 DISCOVER-2 study show continued benefit for Tremfya (guselkumab) for up to two years in adults with active psoriatic arthritis. Previous data demonstrated skin clearance, joint symptom relief, and safety for Tremfya through 24 weeks and one year (Week 52) in a